GB1516738A - Solutions for parenteral perfusion - Google Patents
Solutions for parenteral perfusionInfo
- Publication number
- GB1516738A GB1516738A GB39423/75A GB3942375A GB1516738A GB 1516738 A GB1516738 A GB 1516738A GB 39423/75 A GB39423/75 A GB 39423/75A GB 3942375 A GB3942375 A GB 3942375A GB 1516738 A GB1516738 A GB 1516738A
- Authority
- GB
- United Kingdom
- Prior art keywords
- sodium
- perfusable
- solution
- chloride
- magnesium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000010412 perfusion Effects 0.000 title 1
- 239000000243 solution Substances 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 abstract 2
- 239000011734 sodium Substances 0.000 abstract 2
- 229910052708 sodium Inorganic materials 0.000 abstract 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 208000029663 Hypophosphatemia Diseases 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- 229930182844 L-isoleucine Natural products 0.000 abstract 1
- 239000004395 L-leucine Substances 0.000 abstract 1
- 235000019454 L-leucine Nutrition 0.000 abstract 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229930195722 L-methionine Natural products 0.000 abstract 1
- 229930182821 L-proline Natural products 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 229930003270 Vitamin B Natural products 0.000 abstract 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract 1
- 229960003767 alanine Drugs 0.000 abstract 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229940077731 carbohydrate nutrients Drugs 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 235000021321 essential mineral Nutrition 0.000 abstract 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 abstract 1
- 229960001031 glucose Drugs 0.000 abstract 1
- 229960002989 glutamic acid Drugs 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 150000002315 glycerophosphates Chemical class 0.000 abstract 1
- 229960002885 histidine Drugs 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- 229960003136 leucine Drugs 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- NEKDZOIEWLKCIN-UHFFFAOYSA-K magnesium;zinc;chloride;sulfate Chemical compound [Mg+2].[Cl-].[Zn+2].[O-]S([O-])(=O)=O NEKDZOIEWLKCIN-UHFFFAOYSA-K 0.000 abstract 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract 1
- 229960004452 methionine Drugs 0.000 abstract 1
- 235000005152 nicotinamide Nutrition 0.000 abstract 1
- 239000011570 nicotinamide Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
- 239000001103 potassium chloride Substances 0.000 abstract 1
- 235000011164 potassium chloride Nutrition 0.000 abstract 1
- 229960002429 proline Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 235000008160 pyridoxine Nutrition 0.000 abstract 1
- 239000011677 pyridoxine Substances 0.000 abstract 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
- 229940072172 tetracycline antibiotic Drugs 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229960004799 tryptophan Drugs 0.000 abstract 1
- 229960004295 valine Drugs 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 235000019156 vitamin B Nutrition 0.000 abstract 1
- 239000011720 vitamin B Substances 0.000 abstract 1
- 229940011671 vitamin b6 Drugs 0.000 abstract 1
- 239000000811 xylitol Substances 0.000 abstract 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract 1
- 235000010447 xylitol Nutrition 0.000 abstract 1
- 229960002675 xylitol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2502735A DE2502735B2 (de) | 1975-01-23 | 1975-01-23 | Verwendung von Glycerophosphaten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1516738A true GB1516738A (en) | 1978-07-05 |
Family
ID=5937143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB39423/75A Expired GB1516738A (en) | 1975-01-23 | 1975-09-25 | Solutions for parenteral perfusion |
Country Status (4)
| Country | Link |
|---|---|
| CA (1) | CA1075605A (de) |
| DE (1) | DE2502735B2 (de) |
| GB (1) | GB1516738A (de) |
| ZA (1) | ZA755795B (de) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5916818A (ja) * | 1982-07-20 | 1984-01-28 | Shimizu Seiyaku Kk | 経静脈投与用輸液剤 |
| EP1032403A1 (de) * | 1997-10-24 | 2000-09-06 | Cornell Research Foundation, Inc. | Nahrungsergänzungsmittel für metabolischen hirnleistungsstörungen |
| US8431086B2 (en) | 2006-07-20 | 2013-04-30 | Baxter International Inc. | Medical fluid access device with antiseptic indicator |
| US8485727B2 (en) | 2005-08-02 | 2013-07-16 | Baxter International Inc. | Multiple chamber container |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8701662L (sv) * | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
| GB2544782B (en) * | 2015-11-26 | 2020-07-15 | Fontus Health Ltd | Solution |
-
1975
- 1975-01-23 DE DE2502735A patent/DE2502735B2/de not_active Withdrawn
- 1975-09-11 ZA ZA00755795A patent/ZA755795B/xx unknown
- 1975-09-25 GB GB39423/75A patent/GB1516738A/en not_active Expired
- 1975-10-22 CA CA238,444A patent/CA1075605A/en not_active Expired
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5916818A (ja) * | 1982-07-20 | 1984-01-28 | Shimizu Seiyaku Kk | 経静脈投与用輸液剤 |
| JPS6363534B2 (de) * | 1982-07-20 | 1988-12-07 | ||
| EP1032403A1 (de) * | 1997-10-24 | 2000-09-06 | Cornell Research Foundation, Inc. | Nahrungsergänzungsmittel für metabolischen hirnleistungsstörungen |
| EP1032403A4 (de) * | 1997-10-24 | 2004-03-31 | John P Blass | Nahrungsergänzungsmittel für metabolischen hirnleistungsstörungen |
| US8485727B2 (en) | 2005-08-02 | 2013-07-16 | Baxter International Inc. | Multiple chamber container |
| US8431086B2 (en) | 2006-07-20 | 2013-04-30 | Baxter International Inc. | Medical fluid access device with antiseptic indicator |
Also Published As
| Publication number | Publication date |
|---|---|
| CA1075605A (en) | 1980-04-15 |
| AU8450175A (en) | 1977-03-10 |
| DE2502735B2 (de) | 1978-11-23 |
| ZA755795B (en) | 1976-09-29 |
| DE2502735A1 (de) | 1976-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4172072A (en) | Buffered enzymatically produced metal proteinates | |
| GB1399888A (en) | Injectable amino acid composition | |
| DE69429920T2 (de) | Antemortem futterzusatz für lebendes vieh | |
| SE9402156D0 (sv) | Farmaceutiska kompositioner innehållande salterna av s(+)-2- (4-isobutylfenyl)-propionsyra med basiska aminosyror | |
| DE3069259D1 (en) | A process for enzymatic production of peptides | |
| ES2156699B1 (es) | "preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion". | |
| ZA918893B (en) | Mono-n-substituted 1,4,7,10-tetraazacyclododecane derivatives,process for their production and pharmaceutical agents containing these derivatives | |
| GB1516738A (en) | Solutions for parenteral perfusion | |
| ES8102804A1 (es) | Un metodo para preparar compuestos utiles como precursores de aminoacidos esenciales y semiesenciales | |
| ES363614A1 (es) | Un metodo de preparar una composicion alimenticia de sabor agrandable para consumo humano. | |
| JPS568312A (en) | Amino acid pharmaceutical preparation | |
| SE9003844L (sv) | Naeringstillsats | |
| GB1195381A (en) | Pharmaceutical Compositions Comprising Potassium and Chlorine | |
| CA2134380A1 (en) | Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man | |
| JPS647983B2 (de) | ||
| GB1294812A (de) | ||
| FR2317917A1 (fr) | Melanges de l-aminoacides et leur utilisation therapeutique | |
| JPS57209211A (en) | Antimicrobial composition | |
| GB1304137A (de) | ||
| GB1477732A (en) | Nutrient fluids | |
| ATE155144T1 (de) | Peptidderivate | |
| GB1389858A (en) | Alanine derivatives and their production | |
| Simmonds et al. | Metabolism of phenylalanine-containing peptide amides in Escherichia coli | |
| ES2045092T3 (es) | Un procedimiento de manufactura de un producto farmaceutico para tratamiento de cancer. | |
| GB1261582A (en) | Infusion solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19920925 |